Literature DB >> 30670428

In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex.

Aristine Cheng1, Yi-Tzu Tsai1, Shu-Yuan Chang1, Hsin-Yun Sun1, Un-In Wu1, Wang-Huei Sheng1, Yee-Chun Chen1, Shan-Chwen Chang2.   

Abstract

Infections caused by the difficult-to-treat bacterium Mycobacterium abscessus are increasing in frequency. Rifabutin, in contrast to rifampin, appears to be active in vitro against M. abscessus, especially against clarithromycin-resistant strains. However, explorations for potential synergy between rifabutin and available antimicrobials are currently limited. In vitro synergism between rifabutin and 10 antimicrobials was evaluated in 31 mycobacterial strains by the checkerboard method. The fractional inhibitory concentration index (FICI) was calculated for each rifabutin-based combination. The colony morphology was recorded. Molecular methods for determination of the M. abscessus subspecies and analysis of macrolide resistance were performed by sequencing of the secA1, rpoB, hsp65, erm(41), and rrl genes. Rifabutin yielded an MIC50 of 16 mg/liter (range, 2 to 32 mg/liter) against 26 clinical M. abscessus isolates (comprising 13 M. abscessus subsp. abscessus and 13 M. abscessus subsp. massiliense isolates) and 5 reference strains, including M. abscessus subsp. abscessus ATCC 19977, M. abscessus subsp. bolletii BCRC 16915, M. abscessus subsp. massiliense BCRC 16916, M. chelonae ATCC 35752, and M. peregrinum ATCC 700686. Significant synergism, classified by an FICI of ≤0.5, was demonstrated for the combinations of rifabutin and imipenem in 100% of M. abscessus subsp. abscessus and 69% of M. abscessus subsp. massiliense isolates, and significant synergism for rifabutin and tigecycline was demonstrated in 77% of M. abscessus subsp. abscessus and 69% of M. abscessus subsp. massiliense isolates. Among the 6 clarithromycin-resistant (MICs ≥ 8 mg/liter) M. abscessus subsp. abscessus isolates, the combination of rifabutin and clarithromycin was 100% synergistic. Rifabutin showed promising in vitro synergism with first-line anti-M. abscessus agents, especially for macrolide-resistant M. abscessus subsp. abscessus isolates.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium abscessuszzm321990; imipenem; in vitro synergy; macrolide resistance; rifabutin

Mesh:

Substances:

Year:  2019        PMID: 30670428      PMCID: PMC6437537          DOI: 10.1128/AAC.02234-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 2.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

3.  In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Su-Young Kim; Hee Jae Huh; Nam Yong Lee; Won-Jung Koh; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

Review 4.  ERS International Congress 2021: highlights from the Respiratory Infections Assembly.

Authors:  Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir
Journal:  ERJ Open Res       Date:  2022-05-23

5.  Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem.

Authors:  Siyuan He; Yuzhen Zou; Mengling Zhan; Qi Guo; Yongjie Zhang; Zhemin Zhang; Bing Li; Shaoyan Zhang; Haiqing Chu
Journal:  Infect Drug Resist       Date:  2020-08-18       Impact factor: 4.003

6.  Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.

Authors:  Matt D Johansen; Wassim Daher; Françoise Roquet-Banères; Clément Raynaud; Matthéo Alcaraz; Florian P Maurer; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

Review 8.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

9.  TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus.

Authors:  Jickky Palmae Sarathy; Uday S Ganapathy; Matthew D Zimmerman; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

10.  Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium abscessus subsp. abscessus in vitro.

Authors:  Takahiro Asami; Akio Aono; Kinuyo Chikamatsu; Yuriko Igarashi; Yuta Morishige; Yoshiro Murase; Hiroyuki Yamada; Akiko Takaki; Satoshi Mitarai
Journal:  JAC Antimicrob Resist       Date:  2021-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.